Pelareorep is under clinical development by Oncolytics Biotech and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase II drugs for Pancreatic Ductal Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Pelareorep LoA Report. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Likelihood of Approval and Phase Transition Success Rate Model - Pelareorep in Pancreatic Ductal Adenocarcinoma

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pelareorep overview

Pelareorep (Reolysin) is under development for the treatment of metastatic breast cancer, HER2- breast cancer, refractory multiple myeloma, acute myelocytic leukemia, metastatic colorectal cancer, metastatic triple negative breast cancer, metastatic pancreatic cancer, metastatic colorectal cancer and unresectable anal cancer. The drug candidate is administered as injection or infusion through intravenous, intralesional, intratumoral, intraperitoneal and intrathecal route. Reolysin is a formulation of the human reovirus. It is reovirus type 3 without transgenes. The drug candidate was under development for the treatment of glioblastoma multiforme, relapsed multiple myeloma, ewing sarcoma, malignant fibrous histiocytoma, osteosarcoma, soft tissue sarcoma, fibrosarcoma, leiomyosarcoma, metastatic squamous cell carcinoma of the head and neck, recurrent and refractory astrocytoma, oligodendroglioma, high grade gliomas, medulloblastoma, primitive neuroectodermal tumor (PNET), gastric cancer, metastatic hormone-refractory prostate cancer and muscle-invasive bladder cancer, epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer, advanced or metastatic squamous or non-squamous non-small cell lung cancer (NSCLC), metastatic adenocarcinoma of the pancreas, hepatocellular carcinoma and metastatic melanoma.

Oncolytics Biotech overview

Oncolytics Biotech is a development stage biopharmaceutical company which focuses on the discovery and development of oncolytic viruses for the treatment of cancer. The company’s lead product candidate, pelareorep, is an unmodified reovirus that is an intraosseous (I-O) viral agent indicated for systemic administration for the treatment of hematological malignancies and solid tumors. It is advancing pelareorep as a combination with other products in various clinical phases for the treatment of metastatic breast cancer (BC), early-stage BC, pancreatic cancer, and relapsed or refractory multiple myeloma. Oncolytics Biotech is headquartered in Calgary, Alberta, Canada.

For a complete picture of Pelareorep’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 16 July 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.